

Cross reference to Form 20-F

This table has been provided as a cross reference from the information included in this Annual Report to the requirements of Form 20-F.

Item	Page	Item	Page
1 Identity of directors, senior management and advisers	n/a	8 Financial information	
2 Offer statistics and expected timetable	n/a	A Consolidated statements and other financial information	
3 Key information		Financial statements	See Item 18
A Selected financial data	67	Legal proceedings	102–104
D Risk factors	57	B Significant changes	
4 Information on the company		Note 2 – Post balance sheet event	78
A History and development of the company	06	9 The offer and listing	
B Business overview		A Share price history	158
Products	07–08	C Markets	158
Competition	10	10 Additional information	
Regulation	11	B Memorandum and Articles of Association	35–36
Marketing and distribution	12	C Material contracts	161
Manufacture and supply	13	D Exchange controls	159
Research and development	14–21	E Taxation	156
Intellectual property	22–23	H Documents on display	161
Information technology	23–24	11 Quantitative and qualitative disclosures about market risk	
Environment, health and safety	25	Treasury policies	60–61
Global community partnerships	26–27	Note 34 – Financial instruments and related disclosures	112–115
Access to medicines	28	12 Description of securities other than equity securities	n/a
C Organisational structure	136–141	13 Defaults, dividend arrearages and delinquencies	n/a
D Property, plant and equipment	24	14 Material modifications to the rights of security holders and use of proceeds	n/a
Note 7 – Segment information	88	15 Reserved	
Note 18 – Tangible fixed assets	95	16 Reserved	
5 Operating and financial review and prospects		17 Financial statements	n/a
A Operating results		18 Financial statements	
2000 and 1999	49–57	Directors' statements of responsibility	70
1999 and 1998	62–66	Report by the auditors	71
Under US accounting principles	68	Consolidated statement of profit and loss	72–73
B Liquidity and capital resources	58–61	Consolidated statement of total recognised gains and losses	72–73
C Research and development, patents and licenses, etc.	14–21, 48	Consolidated statement of cash flow	74–75
D Trend information	48	Consolidated balance sheet	76
6 Directors, senior management and employees		Reconciliation of movements in equity shareholders' funds	76
A Directors and senior management	30–32	Company balance sheet	77
B Compensation		Notes to the financial statements	78–135
Remuneration report	37–46	19 Exhibits	n/a
C Board practices			
Corporate governance	32–34		
D Employees			
GlaxoSmithKline people	24		
Note 35 – Employee costs	116		
Financial record	152		
E Share ownership			
GlaxoSmithKline people	24		
Note 33 – Employee share schemes	108–111		
7 Major shareholders and related party transactions			
A Major shareholders	159		
B Related party transactions	161		

Cautionary factors that may affect future results

Cautionary Statements under the US Private Securities Litigation Reform Act of 1995

The Group's Annual Report and Accounts and its period reports filed with the US Securities and Exchange Commission (the 'Commission'), including this Annual Report on Form 20-F for the year ended 31st December 2000 (the '2000 Form 20-F'), contain, and written information released, or oral statements made to the public in the future by or on behalf of the Group may contain, forward-looking statements. Forward-looking statements give the Group's current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as 'anticipate', 'estimate', 'expect', 'intend', 'will', 'project', 'plan', 'believe', and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results.

Any or all of the Group's forward-looking statements in the 2000 Form 20-F, in reports filed with the Commission, or in any other public statements the Group makes, may turn out to be incorrect. They can be affected by inappropriate or inaccurate assumptions the Group might use as a basis for such forward-looking statements or by known or unknown risks and uncertainties. Many factors mentioned in the discussion of the Group's business in the 2000 Form 20-F will be important in determining future results. Consequently, no forward-looking statement should be viewed as or can be guaranteed. Actual future results may vary materially.

The Group undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Investors should also note the cautionary discussion of risks and uncertainties relevant to the Group's business set out under 'Risk factors' (page 57). This discussion is provided as permitted by the US Private Securities Litigation Reform Act of 1995.

Related party transactions

GlaxoSmithKline has a 27 per cent interest in Quest Diagnostics Inc. The activities of Quest are not part of the company's core business, and the interest is held only as an investment.

Material contracts

The Boards of Glaxo Wellcome plc and SmithKline Beecham plc announced on 17th January 2000 the terms of an agreement for the proposed merger of the two companies. The merger was implemented by way of a scheme of arrangement on 27th December 2000, on which date GlaxoSmithKline plc acquired the whole of the issued share capital of Glaxo Wellcome plc and SmithKline Beecham plc.

On 18th January 2001 GlaxoSmithKline completed the acquisition of Block Drug Company Inc, a manufacturer of toothpaste and other oral healthcare and consumer products, for US\$1,240 million (£832 million).

Documents on display

Documents referred to in this Annual Report are available for inspection at the Registered Office of the company.